Effect of metformin on progression-free survival outcomes in patients with advanced or metastatic HR+, HER2-breast cancer: subgroup analysis of STEPAUT

被引：0
|
作者：
Egle, D. [1 ]
Marth, C. [1 ]
Steger, G. [2 ,3 ]
Bartsch, R. [2 ,3 ]
Pfeiler, G. [4 ]
Greil, R. [5 ]
Helfgott, R. [6 ]
Oehler, L. [7 ]
Hennebelle, M. [8 ]
Gnant, M. [3 ,9 ]
机构：
[1] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[2] Med Univ Vienna, Dept Oncol, Vienna, Austria
[3] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
[4] Med Univ Vienna, Dept Gynecol & Gynecol Oncol, Vienna, Austria
[5] Med Univ Salzburg, Dept Oncol, Salzburg, Austria
[6] Hosp Sisters Char, Dept Surg, Linz, Austria
[7] St Josephs Hosp Vienna, Dept Oncol, Vienna, Austria
[8] Novartis Pharma GmbH, Vienna, Austria
[9] Med Univ Vienna, Dept Surg, Vienna, Austria
来源：
BREAST | 2017年 / 32卷
关键词：
D O I：
10.1016/S0960-9776(17)30115-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P014
引用
收藏
页码：S26 / S27
页数：2
相关论文
共 50 条
  • [21] Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib plus letrozole in postmenopausal patients with advanced HR+/HER2-breast cancer
    O'Shaughnessy, Joyce
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon-Sim
    Sonke, Gabe
    Hart, Lowell
    Campone, Mario
    Petrakova, Katarina
    Winer, Eric P.
    Janni, Wolfgang
    Conte, Pierfranco
    Cameron, David A.
    Andre, Fabrice
    Arteaga, Carlos
    Zarate, Juan Pablo
    Chakravartty, Arunava
    Taran, Tetiana
    Le Gac, Fabienne
    Serra, Paolo
    Hortobagyi, Gabriel N.
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [22] Abemaciclib for Patients with advanced or metastatic HR plus Breast Cancer and HER2-Breast Cancer Benefits in Overall Survival - even in Patients with visceral Metastases
    Ruedesheim, Sabine M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
  • [23] Chemoprotective effect of metformin against HR+/HER2-breast cancer among women with type-2 diabetes.
    Chikermane, Soumya
    Abughosh, Susan M.
    Sharma, Manvi
    Trivedi, Meghna V.
    Aparasu, Rajender R.
    Johnson, Michael L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] IN ADVANCED/METASTATIC BREAST CANCER, IS PROGRESSION-FREE SURVIVAL A SURROGATE OUTCOME?
    Franca, A. C.
    Schroeder, L.
    Padilla, M.
    Meirelles, I
    Silva, A. S.
    Magliano, C.
    Santos, M.
    [J]. VALUE IN HEALTH, 2020, 23 : S477 - S478
  • [25] Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    Denise A. Yardley
    Shinzaburo Noguchi
    Kathleen I. Pritchard
    Howard A. Burris
    José Baselga
    Michael Gnant
    Gabriel N. Hortobagyi
    Mario Campone
    Barbara Pistilli
    Martine Piccart
    Bohuslav Melichar
    Katarina Petrakova
    Francis P. Arena
    Frans Erdkamp
    Wael A. Harb
    Wentao Feng
    Ayelet Cahana
    Tetiana Taran
    David Lebwohl
    Hope S. Rugo
    [J]. Advances in Therapy, 2014, 31 : 1008 - 1009
  • [26] The transcription factor CBFB mutations indicate an improved survival in HR+/HER2-breast cancer
    Guo, Liping
    Chen, Bo
    Zhang, Guochun
    Wang, Yulei
    Cao, Li
    Ren, Chongyang
    Wen, Lingzhu
    Lin, Jiali
    Wei, Guangnan
    Liao, Ning
    [J]. GENE, 2020, 759
  • [27] Controversial topics in metastatic HR+/HER2-breast cancer: Guiding treatment by a modified Delphi approach
    Fabi, Alessandra
    Buono, Giuseppe
    Bria, Emilio
    Bianchini, Giampaolo
    Curigliano, Giuseppe
    De Laurentiis, Michelino
    De Placido, Sabino
    Del Mastro, Lucia
    Guarneri, Valentina
    Generali, Daniele
    Livi, Lorenzo
    Lorusso, Vito
    Montemurro, Filippo
    Puglisi, Fabio
    Vigneri, Paolo
    Zambelli, Alberto
    Arpino, Grazia
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    [J]. ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
  • [29] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    [J]. CANCER RESEARCH, 2016, 76
  • [30] BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Velchev, M.
    Vekov, T.
    [J]. VALUE IN HEALTH, 2018, 21 : S22 - S22
12345